Search
Searching Content by Jayita Guhaniyogi from Foley & Lardner ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Blocking Patent Discounts Objective Indicia Of Non-Obviousness
In Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., the Federal Circuit affirmed the district court decision finding four Acorda Orange Book-listed patents for Ampyra® invalid as obvious.
United States
4 Oct 2018
2
Federal Circuit Finds ANDA Jurisdiction Before PIV Certification
Our first article on Vanda Pharmaceuticals, Inc. v. Aventisub, LLC focused on the subject matter eligibility of the personalized method of treatment claims under 35 USC § 101.
United States
9 May 2018
3
FDA Marketing Exclusivity Periods Limited To Same Active Moiety
In Otsuka Pharm. Co., Ltd. v. Price, the US Court of Appeals for the District of Columbia Circuit affirmed the district court decision upholding FDA's "same moiety" test for defining the zone of FDA market exclusivity periods.
United States
12 Sep 2017
4
Impact Of TC Heartland On ANDA And Biosimilar Litigation
In TC Heartland, the Supreme Court held that its 1957 decision in Fourco was still good law that limited the definition of "residence" under 28 U.S.C. § 1400(b) to the state of incorporation for domestic...
United States
20 Jul 2017
Links to Result pages
 
1